Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No more stop losses at $3 ??
DARPA sees it completely different. If only they would have done their due diligence... oh wait, maybe they did!
which patent ? the pending one? or the one for cancer ?
The wheels are spinning, the trials are starting, now time has to do Its job.
I presume any raise in capital later in the year will be again with the warrants.
Our 80 patient trial is open-label so we can have data readout all through the year.
Interesting:
"have enough cash to get through most of 2017. With the kinds of programs we’re running, at some point this year we will be looking for capital. But it’s not critical at this point in time and we have enough money to comfortably get through most of the year."
We will be filing an IND and opening a trial with our second product, TPIV 110, sometime in first quarter
I go with the companies SEC form which says the patent is pending. As we could read this week, the discussion with USPTO is still ongoing.
Alternative fact?
Lets focus on getting a patent before discussing ways to extend it...
It clearly says patent pending. So nothing dubious here.
Just a factual statement.
The Alzheimer protection is the key to future partnership.
Please elaborate your reasoning.
And patent issuance, unequivocally, is the key to any future partnership. Absence a resolution, I believe no major pharma company will invest their dollars. Does that mean nobody is interested? no of course not, but I would not buy somebody else's house without making sure he actually owns it,
To make life easy: http://www.anavex.com/?news=anavex-announces-fiscal-2015-year-end-financial-results
Relevant part:
On August 12, 2015, Anavex announced that it had received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. The patent was subsequently issued on November 10, 2015 as patent number 9,180,106 and is expected to provide intellectual property protection until at least 2030.
Seriously? One link is in your post and the other one is easily found on the Anavex PR archive from 2015
As for the money, luckily we have no such experience (yet) at Anavex.
But according to the latest 10k the patent is pending, which contradicts 2 PR's from 2015 regarding patents
Then why does the 10k say the patent is pending?
So for once and for all: 2-73 either mono or combo is at the moment not protected by patents, pending a decision on the patent application.
No argument here, but the 10k contradicts public statement that there are no IP-issues. How can a patent pending equal IP-protection?
From the latest 10k, page 14:
Our primary patent applications for ANAVEX TM 2-73 and the combination of ANAVEX TM 2-73 with donepezil are pending only in the United States Patent and Trademark Office. The lack of patent protection in global markets may inhibit our ability to advance our compounds and may make Anavex less attractive to potential partners.
Basically it are existing warrants translated into shares for sale?
And it has already failes multiple P3's at GSK.
they sold it for 5 mil. Yeah they would sell a good drug for peanuts...
Never good to underestimate market forces and their manipulators. AF will be against Anavex with full force until he can no longer deny it.
Any free money is always good, means less dillution!
I would not think that this board or other Anavex groups are being tracked by tutes.
Why would an institution spent 2k buying Anavex?? Seems hardly worth it. Tutes logic I guess?
Not sure what your point is but I was objecting to a thought that Rett would pay whatever the bill would be, based on using the word 'minimum' in the PR
Anavex provides 2-73 and Rett 600.000 mil. Until proved otherwise, as an investor I assume worst case: Anavex pays the remaining 400.000. In the bigger scheme this is still peanuts.
You have a source on that?
I see it very simple: Missling reckons it costs a million, Rett foundations pays at least 600.000 and Anavex chips in whatever is left.
So therefore Rett would fund the total cost of the trial?
Reas Missling on Marketwatch, he says the exoected cost is 1 million. If Rett was to pay it all, they would have said so.
The context was an implication that if more money was needed that Rett would cough it up. I disagree on that. Any remaining bills will be for Anavex to pay.
Confirmation from REtt Syndrome of Funding for Phase 2/3:
It also says "to cover the majority of a trial", so that makes me conclude that any remaining costs are for Anavex.
The FDA is not twiddling its thumbs. As dr Missling has stated, they are working with the FDA in designing the p2/3 protocol.
Back up the statement with a source
some of the patients of the 25 that are on the AVXL trial were on the Prana trial with Mc Farlane
So we do not know if Australia is providing funds. Sure based on previous grants it is a valid option, but not a fact.
Funding for p2/3 is still a public mystery.
Do we know Australia is paying or do we think it?
Why? Trial commencement was PR'ed last week and fast track was granted A while back
Reasons were never necessary in the past to make outrageous price predictions. Thought I might give it a go too.